Gossamer Bio Inc. (GOSS) Tops Q3 EPS by 5c

Gossamer Bio Inc. (NASDAQ: GOSS) reported Q3 EPS of ($0.80), $0.05 better than the analyst estimate of ($0.85).

“We are very excited about the continued advancement of our pipeline with the start of two robust Phase 2 clinical trials for GB002 and GB004 and the planned dose expansion cohort for GB1275,” said Sheila Gujrathi, M.D., Co-Founder and Chief Executive Officer of Gossamer. “We believe that these clinical programs hold tremendous potential to benefit high unmet need patient populations.”

For earnings history and earnings-related data on Gossamer Bio Inc. (GOSS) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
• Qualcomm investor day to detail data center plans Wednesday